BACE1 cleaves amyloid‑precursor protein (APP) at the β‑site, generating the amyloid‑β (Aβ) peptides that aggregate into plaques—a hallmark of AD pathology. SONE‑214 binds competitively to the catalytic aspartate dyad (Asp32/Asp228) of BACE1 with a Ki ≈ 0.9 nM, thereby blocking Aβ production.
Key mechanistic features:
You may have seen the term “SONE-214” in a datasheet, patent filing, maintenance log, or conversation—and wondered what it means. While the code itself is ambiguous without context, this guide walks through likely interpretations, how to identify the correct one, and what to do next. SONE-214
| Model | Dose | Administration | Outcome | |-------|------|----------------|---------| | APP/PS1 transgenic mice | 10 mg kg⁻¹ day⁻¹ | Oral, BID | ↓ Aβ40/42 in brain (71 %) and CSF (66 %); ↓ plaque load by 58 % after 12 weeks. | | 3xTg‑AD mice | 30 mg kg⁻¹ day⁻¹ | Oral, QD | Improved Morris water‑maze latency (30 % faster) and reduced phospho‑tau (Ser202) by 44 % after 6 months. | | Pharmacokinetic/PD correlation | – | – | Brain exposure (Cmax ≈ 0.9 µM) correlated with ≥ 70 % Aβ reduction. | | Safety pharmacology | Up to 300 mg kg⁻¹ day⁻¹ | Oral | No adverse effects on cardiovascular, respiratory or CNS parameters in rats & dogs. | You may have seen the term “SONE-214” in
SONE-214 has circulated in niche technical and industrial communities as a shorthand that can refer to either a specific product code, a material grade, or an internal project name depending on context. Below I outline plausible interpretations, technical characteristics, potential applications, and the strategic implications for teams working with—or encountering—something labeled SONE-214. I assume you want a blog-style, informative post aimed at a technical or business audience; if you meant a different tone or audience, tell me and I’ll adapt. this guide walks through likely interpretations